Arthur Swislocki, M.D.
Endocrinology, Diabetes, and Metabolism
- Professor in Residence, Step III
Philosophy of Care
Dr. Swislocki tries to involve the patient as a team member since the conditions we are treating are lifelong and require the patient's active involvement to the best of their ability. His role is to educate and encourage them, and to provide them the resources they need to be successful.
Dr. Swislocki is board-certified in Internal Medicine and Endocrinology and Metabolism. His practice is almost entirely by referral and clinic-based. His primary interest is in disorders of insulin resistance, such as hypertension, diabetes, and diabetes complications, but he is also interested in caring for patients with chronic metabolic diseases such as obesity and osteoporosis. He enjoys caring for patients with other endocrine diseases as well.
Disorders of insulin resistance, specifically: Hypertension, diabetes mellitus, complications of diabetes mellitus, and pathophysiology of insulin resistance. He is also interested in delivery of health care to people with chronic metabolic diseases, including diabetes, hypertension, and osteoporosis.
Endocrinology, Diabetes, and Metabolism
M.D., UCLA School of Medicine, Los Angeles, California, 1979
B.A., UCLA, Los Angeles, California, 1972
M.A., UCLA, Los Angeles, California, 1973
UC Davis Medical Center, Sacramento, CA, 1980-82
UC Davis Medical Center (Chief Resident), Sacramento, CA, 1982-83
Stanford University Medical Center, Stanford, CA, 1984-86
American Board of Endocrinology, Diabetes and Metobolism, 1989
American Board of Internal Medicine, 1982
American College of Physicians
American Diabetes Association
American Federation for Medical Research
The Endocrine Society
Honors and Awards
Member, VISN 21 Endocrinology Advisory Board, 2012
Recognition as an "Outstanding Reviewer," by the Editor, Annals of Internal Medicine, 2009
Recognition as an "Outstanding Reviewer," by the Editor, Annals of Internal Medicine, 2008
Attending of the year, Medical Service, Martinez DVAMC, 1990
Select Recent Publications
Kelley, D.S., Y. Adkins, L. R Woodhouse, A. Swislocki, B. E. Mackey, and D. Siegel (2012). DHA Supplementation Improved Lipocentric But Not Glucocentric Markers of Insulin Sensitivity in Hypertriglyceridemic Men. Metab Syndr Relat Disord; 10: 32-38.
Swislocki, A.L.M., D. Siegel, and I. Jialal (2012). Pharmacotherapy for the Metabolic Syndrome. Invited Review, Curr Vasc Pharmacol; 10: 187-205.
Swislocki, A.L.M., J.L. Meier, S.M. Najera, and R. H. Noth (2011). Long-term maintenance of glucose control in veterans with type 2 diabetes mellitus using oral agents. Metab Syndr Relat Disord; 9: 469-73.
Garcia, E., J.R. Lopez, J.L. Meier, A.L.M. Swislocki, and D. Siegel (2011). Resistant Hypertension and Undiagnosed Primary Hyperaldosteronism Detected by Use of a Computerized Database. J Clin Hypertens, 13: 487-491.
Libby, A., J. Meier, J. Lopez, A.L.M. Swislocki, and D. Siegel (2010). The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin. Metab Syndr Relat Disord; 8:79-84.
Siegel, D, and A.L.M. Swislocki (2010). Hypertensive Treatment in Patients with the Metabolic Syndrome. Invited review, Metab Syndr Relat Disord; 8: 95-103.
Siegel, D, and A.L.M. Swislocki (2011). The ACCORD Study: The Devil is in the Details. Invited commentary. Metab Syndr Relat Disord; 9: 81-4. 2010 Dec 18. [Epub ahead of print]
A. Swislocki, J.A. Green, G. Heinrich, C.A. Barnett, I. Meadows, E.B. Harmon, and R. Noth (2010). Prevalence of osteoporosis in a male nursing home population. Am J Man Care; 16: 427-33.
Swislocki, A, M. Orth, M. Bales, J. Weisshaupt, C. West, J. Edrington, B. Cooper, L. Saputo, M. Islas, and C. Miaskowski (2010). A randomized controlled trial of the effectiveness of photon stimulation on pain, sensation, and quality of life in patients with diabetic peripheral neuropathy. J Pain Symptom Manage; 39: 88-99. Epub 2009 Nov 5.
Keane, J, J.L. Meier, R.H. Noth, and A.L.M. Swislocki (2009). Computer-based screening of veterans for metabolic syndrome. Metab Syndr Relat Disord, 7: 557-61.